Validation of the Turkish Version of PTSD-RI-5

Sponsor
Melek Ince (Other)
Overall Status
Recruiting
CT.gov ID
NCT06077474
Collaborator
(none)
155
1
13.9
11.2

Study Details

Study Description

Brief Summary

The aim of this study is to investigate the adaptation and validity of the DSM-5 PTSD-RI -5 scale in patients who have been exposed to traumatic events. Thus, a scale useful for the diagnosis and follow-up of PTSD will be presented to the Turkish population.

Condition or Disease Intervention/Treatment Phase
  • Other: Testing the the DSM-5 UCLA Posttraumatic Stress Disorder Reaction Index Self-Report Scale for Children and Adolescents (PTSD-RI-5)

Detailed Description

Children worldwide are at risk of experiencing psychological trauma. In addition, one in every four children experiences major traumatic events such as domestic, school, or social violence, abuse, vehicle accidents, serious medical diseases, terrorist incidents, and war. These difficult experiences increase the incidence of post-traumatic stress disorder in children. It is reported that approximately 30% of children who have been exposed to trauma develop post-traumatic stress disorder. Although it is sometimes difficult to diagnose post-traumatic stress disorder, it is important to detect symptoms of PTSD in children and adolescents early. Many internalizing and externalizing symptoms occur in PTSD; There may be separation anxiety, shame, guilt, low tolerance, overstimulation, impulsivity, outbursts of anger, hostility, defiance, aggression, irritability, and mood changes. Therefore, early evaluation of trauma experience and post-traumatic symptoms in children and adolescents seems important.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
155 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Validation and Reliability of the Turkish Version of the UCLA Posttraumatic Stress Disorder (PTSD) Reaction Index (RI) for The Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 Self Report for Children and Adolescents
Actual Study Start Date :
Oct 5, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
PTSD QUESTIONNAIRES

The group is anticipated to consist of in 155 patients who have been exposed to traumatic events.

Other: Testing the the DSM-5 UCLA Posttraumatic Stress Disorder Reaction Index Self-Report Scale for Children and Adolescents (PTSD-RI-5)
Administer the DSM-5 PTSD-RI-5 scale in 155 patients with exposed to traumatic events.
Other Names:
  • Severity of Post-Traumatic Stress Symptoms -Child aged 11-17 Post-Traumatic Stress Disorder National Stressful Events Survey Short Form (NSESSS)
  • Outcome Measures

    Primary Outcome Measures

    1. Reliability of PTSD-RI-5 [Baseline]

      Internal consistency will be tested with Cronbach Alpha coefficient. Test-retest reliability will be tested with intraclass correlation coefficient (ICC).

    2. Reliability of PTSD-RI-5 [At the end of the 2nd week of study]

      Test-retest reliability will be tested with intraclass correlation coefficient (ICC).

    3. Correlation between the PTSD-RI-5 and Post-Traumatic Stress Disorder National Stressful Events Survey Short Form [Baseline]

      The Spearman Correlation Analysis will be used for the correlation between between the PTSD-RI-5 and Post-Traumatic Stress Disorder National Stressful Events Survey Short Form

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    11 Years to 17 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Being a child or adolescent between the ages of 11-17

    • To have experience a traumatic event in the past

    • To have cognitive capacity to understand and complete the survey.

    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dr. Behcet Uz Pediatric Diseases And Surgery Training And Research Hospital İzmir Turkey

    Sponsors and Collaborators

    • Melek Ince

    Investigators

    • Study Chair: Fatma S Durak, MD, Dr. Behcet Uz Children's Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Melek Ince, MD, Dr. Behcet Uz Children's Hospital
    ClinicalTrials.gov Identifier:
    NCT06077474
    Other Study ID Numbers:
    • 38583858
    First Posted:
    Oct 11, 2023
    Last Update Posted:
    Oct 11, 2023
    Last Verified:
    Oct 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 11, 2023